Pacific Biosciences (PACB)
PACBPacific Biosciences
-$0.04 (-0.13%)

Pacific Biosciences Stock Analysis & Ratings

Pacific Biosciences Stock Analysis Overview

Smart Score
Learn more about TipRanks Smart Score
The Pacific Biosciences stock analysis is based on the TipRanks Smart Score which is derived from 8 unique data sets including Analyst recommendations, Crowd Wisdom, Hedge Fund Activity, Media Sentiment and multiple Technical stock factors. The Smart Score is a quantitative, data-driven rating system and does not include human intervention.

Stock Chart


PACB Stock Stats

Previous Close$31.35
Bid31.65 x 5
Ask31.78 x 1
Today’s Range$0 - $0
52-Week Range$3.57 - $53.69
Average Volume2.68M
Market Cap$6.24B
P/E Ratio-112.1
Earnings DateAug 03, 2021

Company Description

Pacific Biosciences

Pacific Biosciences of California, Inc. engages in the development, manufacture and sale of an integrated platform for genetic analysis. Its products and services include PacBio sequel system, consumables, analytical software, and single molecule real-time (SMRT) compatible products. It operates through the following geographical segments: North America, Europe, and Asia Pacific. The company was founded by Stephen Turner and Joseph Vincent Bonventre on July 14, 2000 and is headquartered in Menlo Park, CA.
Medical Diagnostics & Research
Christian O. Henry
1305 O'Brien Drive, Menlo Park, CA, 94025, US


P/E Ratio Range

The price to earnings ratio. This is used by investors to assess a stock’s market price relative to its earnings.


What was Pacific Biosciences’s price range in the past 12 months?
Pacific Biosciences lowest stock price was $3.57 and its highest was $53.69 in the past 12 months.
    What is Pacific Biosciences’s market cap?
    Pacific Biosciences’s market cap is $6.24B.
      What is Pacific Biosciences’s price target?
      The average price target for Pacific Biosciences is $30.00. This is based on 1 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
      The highest analyst price target is $30.00 ,the lowest forecast is $30.00. The average price target represents -4.31% Decrease from the current price of $31.35.
        What do analysts say about Pacific Biosciences?
        Pacific Biosciences’s analyst rating consensus is a ‘Hold. This is based on the ratings of 1 Wall Streets Analysts.
          When is Pacific Biosciences’s upcoming earnings report date?
          Pacific Biosciences’s upcoming earnings report date is Aug 03, 2021 which is in 10 days.
            How were Pacific Biosciences’s earnings last quarter?
            Pacific Biosciences released its earnings results on Apr 29, 2021. The company reported -$0.449 earnings per share for the quarter, beating the consensus estimate of -$0.459 by $0.01.
              Is Pacific Biosciences overvalued?
              According to Wall Street analysts Pacific Biosciences’s price is currently Overvalued.
                Does Pacific Biosciences pay dividends?
                Pacific Biosciences does not currently pay dividends.
                What is Pacific Biosciences’s EPS estimate?
                Pacific Biosciences’s EPS estimate for its next earnings report is not yet available.
                How many shares outstanding does Pacific Biosciences have?
                Pacific Biosciences has 199,010,000 shares outstanding.
                  What happened to Pacific Biosciences’s price movement after its last earnings report?
                  Pacific Biosciences reported an EPS of -$0.449 in its last earnings report, beating expectations of -$0.459. Following the earnings report the stock price went down -11.24%.
                    Which hedge fund is a major shareholder of Pacific Biosciences?
                    Among the largest hedge funds holding Pacific Biosciences’s share is ARK Investment Management LLC. It holds Pacific Biosciences’s shares valued at 710M.

                      What's Included in PREMIUM?
                      Make informed decisions based on Top Analysts' activity
                      Know what industry insiders are buying
                      Get actionable alerts from top Wall Street Analysts
                      Find out before anyone else which stock is going to shoot up
                      Get powerful stock screeners & detailed portfolio analysis